FBR Doubles Turnover Tax on Pharmaceutical Distributors: Key Compliance Update for Drug Wholesalers
The turnover tax on wholesalers and distributors has been doubled to 0.5%, marking a significant policy shift that practitioners advising pharmaceutical distribution businesses must immediately act upon for tax year 2026-27.
The New Rate: Impact and Timeline
This change represents a substantial increase from the prior rate and applies specifically to pharmaceutical distributors and wholesalers operating under the Sales Tax Act.
The Finance Bill proposes to withdraw the aforesaid reduced rate of 0.25 per cent that previously applied to pharmaceutical products distributors, cement dealers, steel distributors and FMCG wholesalers. The doubling to 0.5 per cent is now active policy and will significantly affect compliance calculations for affected businesses.
Who Is Affected
The new rate targets entities in the pharmaceutical supply chain—specifically wholesalers, distributors, and sub-dealers of pharmaceutical products. Practitioners should verify whether their clients fall within this category, as the distinction between retail, wholesale and distribution status is critical to correct application of the turnover tax. Businesses previously benefiting from the lower 0.25 per cent rate must now recalculate their minimum tax liability.
Calculation and Compliance
Turnover tax (also called minimum tax on turnover) is calculated as a percentage of annual gross turnover. It is payable by businesses registered under the Sales Tax Act, 1990, even where normal tax (income tax or super tax) liability is lower or absent due to reported losses. The minimum turnover tax is payable in cash and is not always adjustable against income tax liability in full.
Under the Finance Act framework, practitioners must ensure that clients:
- File income tax returns showing actual turnover correctly
- Calculate minimum tax at the new 0.5 per cent rate for tax year 2026
- Make timely payment to avoid default surcharge
- Verify that no prior year adjustments are available (unless specifically allowed under law)
Interaction with Income Tax Assessment
A critical point for accountants: the new turnover tax rate does not relieve a distributor of normal income tax filing and assessment obligations. Where a pharmaceutical distributor reports a taxable profit, it must pay income tax. Where turnover tax exceeds normal tax, the excess (under certain conditions) may be carried forward for adjustment against future years' normal tax. However, practitioners should not assume carryforward rights without reviewing the specific provisions of Section 113 of the Income Tax Ordinance, 2001, as amended.
Implementation and Documentation
Businesses should amend their accounting policies to reflect the new 0.5 per cent rate in calculations for quarterly advance tax (where applicable) and annual return filing. For clients operating in Pakistan's federal sales tax system, the impact on IRIS portal entries must be carefully modelled. Any instalment payments or advance tax estimates already filed for the 2026 tax year should be reviewed for sufficiency against the revised minimum liability.
Practitioner Next Steps
Accountants should:
- Identify all clients in pharmaceutical wholesale, distribution and sub-dealing
- Recalculate turnover tax liability at 0.5 per cent (doubled from prior 0.25 per cent rate)
- Update tax provision schedules in financial statements for 2026
- Advise clients on timing of payment to meet FBR deadlines
- Review any pending refund claims or assessment orders to ensure no unintended interaction with the rate change
This increase forms part of the government's broader Finance Act 2026 reforms aimed at rationalising reduced-rate regimes and broadening the tax base.
This is an AI-assisted summary of recent FBR policy. Practitioners should verify all figures and filing deadlines against official FBR notifications and the Finance Act 2026 before advising clients.